Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a highly aggressive monogenic cancer driven by SMARCA4 mutations. Here, we report responses to anti-PD1 immunotherapy in four patients and characterize the immune landscape of SCCOHT tumors using quantitative immunofluorescence and g...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute Jg. 110; H. 7; S. 787
Hauptverfasser: Jelinic, Petar, Ricca, Jacob, Van Oudenhove, Elke, Olvera, Narciso, Merghoub, Taha, Levine, Douglas A, Zamarin, Dmitriy
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.07.2018
Schlagworte:
Adolescent
Adult
Antibodies, Monoclonal - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
B7-H1 Antigen - immunology
Carcinoma, Small Cell - drug therapy
Carcinoma, Small Cell - genetics
Carcinoma, Small Cell - immunology
Carcinoma, Small Cell - pathology
Cell Cycle Checkpoints - drug effects
Cell Cycle Checkpoints - immunology
DNA Helicases - genetics
Female
Humans
Hypercalcemia - complications
Hypercalcemia - genetics
Hypercalcemia - immunology
Hypercalcemia - pathology
Immunotherapy - methods
Mutation
Nuclear Proteins - genetics
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Ovarian Neoplasms - immunology
Ovarian Neoplasms - pathology
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - immunology
Rationalization
Transcription Factors - genetics
Tumor Microenvironment - drug effects
Tumor Microenvironment - immunology
Young Adult
ISSN:1460-2105, 1460-2105
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a highly aggressive monogenic cancer driven by SMARCA4 mutations. Here, we report responses to anti-PD1 immunotherapy in four patients and characterize the immune landscape of SCCOHT tumors using quantitative immunofluorescence and gene expression profiling. Unexpectedly for a low mutation burden cancer, the majority of the tumors (eight of 11 cases) demonstrated PD-L1 expression with strong associated T-cell infiltration (R2 = 0.60-0.95). PD-L1 expression was detected in both tumor and stromal cells, with macrophages being the most abundant PD-L1-positive cells in some tumors (three of 11 cases). Transcriptional profiling revealed increased expression of genes related to Th1 and cytotoxic cell function in PD-L1-high tumors, suggesting that PD-L1 acts as a pathway of adaptive immune resistance in SCCOHT. These findings suggest that although SCCOHT are low-mutational burden tumors, their immunogenic microenvironment resembles the landscape of tumors that respond well to treatment with PD-1/PD-L1 blockade.
Bibliographie:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1460-2105
1460-2105
DOI:10.1093/jnci/djx277